Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Bristol-Myers Squibb receives approval in Japan for Sprycel

Jan. 22, 2009

S*BIO grants worldwide exclusive license to Tragara to develop and commercialize SB-1317

Jan. 22, 2009

Synergy seen with PARP-1 inhibitor BSI-401 and oxaliplatin in pancreatic cancer model

Jan. 21, 2009

Antitumor activity increased with PLX-4032, capecitabine and bevacizumab in colorectal cancer model

Jan. 21, 2009

FDA grants orphan drug status to omacetaxine for myelodysplastic syndromes

Jan. 21, 2009

Early phase II results show some activity with ARC-100 in pancreatic cancer patients

Jan. 21, 2009

MMRC and Merck & Co. initiate phase II Zolinza trial in multiple myeloma

Jan. 20, 2009

Brivanib plus cetuximab more effective in K-ras wild-type colorectal cancer patients

Jan. 20, 2009

Normal and partially transformed human embryonic stem cells differentiated

Jan. 20, 2009

New ERK2 inhibitors with oncolytic activity reported in recent Schering-Plough patent

Jan. 20, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...